Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.47 - $2.03 $285,863 - $394,763
194,465 New
194,465 $299,000
Q3 2023

Nov 14, 2023

BUY
$2.66 - $4.33 $26,469 - $43,087
9,951 Added 22.0%
55,192 $164,000
Q2 2023

Aug 14, 2023

BUY
$2.05 - $6.1 $92,744 - $275,970
45,241 New
45,241 $201,000
Q2 2019

Aug 14, 2019

SELL
$3.06 - $51.61 $385 - $6,502
-126 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$31.16 - $48.62 $467 - $729
-15 Reduced 10.64%
126 $5,000
Q4 2018

Feb 14, 2019

BUY
$23.33 - $36.37 $3,289 - $5,128
141 New
141 $5,000
Q3 2018

Nov 14, 2018

SELL
$29.34 - $35.0 $2,992 - $3,570
-102 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$27.33 - $41.46 $1,448 - $2,197
-53 Reduced 34.19%
102 $3,000
Q1 2018

May 15, 2018

BUY
$20.21 - $32.0 $3,132 - $4,960
155 New
155 $4,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $99M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.